Here are the 10-K annual reports from Medinotec Inc (MDNC) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow MDNC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDNC filings page.
Medinotec, Inc., a Nevada-based medical device company with core operations in Johannesburg, files its annual report describing a niche portfolio of balloon catheters and airway dilation products and an evolving global distribution network. The company earns revenue from proprietary devices such as the Trachealator and Outflo Aortic Valve Dilation Balloon Catheter, plus third‑party cardiology and dialysis products, with business still heavily concentrated in South Africa.
U.S. sales reached $611,860 in fiscal 2026, about 6% of total sales, compared with $678,105 and 7% a year earlier, underscoring early but limited traction in the American market despite FDA 510(k) clearances for Trachealator and Outflo. As of February 28, 2026, the Medinotec Group employed 36 full‑time staff and 12 independent contractors, supporting development, manufacturing, regulatory affairs, and commercialization across roughly 45 countries.
The report highlights significant dependencies and risks: approximately 89% of revenue comes from sales to DISA Life Sciences in South Africa, exposing Medinotec to both customer and geographic concentration. Operations are further shaped by South African power instability, exchange controls, foreign‑exchange volatility and potential changes to U.S. trade benefits such as AGOA. Management outlines a three‑pillar strategy focused on expanding its proprietary product portfolio, strengthening internal manufacturing and quality systems under ISO 13485 and MDR, and selectively pursuing acquisitions or new distribution arrangements while managing liquidity needs and potential shareholder dilution from future capital raises.